Core Viewpoint - A federal securities class action has been filed against Charming Medical Ltd. for alleged violations of the Securities Exchange Act of 1934, following a significant and artificial increase in its stock price during the class period from October 21, 2025, to November 12, 2025 [1][2]. Group 1: Allegations and Stock Performance - The lawsuit claims that Charming Medical's stock price surged from $4.00 to a high of $29.36 without any fundamental news, indicating potential market manipulation [2]. - Plaintiffs allege that the price increase was driven by a fraudulent social-media-based stock promotion scheme, where impersonators posed as financial advisors to promote the stock with unsupported claims [3]. - Trading in Charming Medical securities was suspended in November 2025, revealing the artificial nature of the stock price increase and leading to investor losses [4]. Group 2: Legal Proceedings and Investor Actions - The proposed class includes all individuals and entities who purchased Charming Medical securities during the class period and suffered damages, excluding defendants and their affiliates [4]. - Investors have until February 17, 2026, to seek appointments as lead plaintiff in the class action [1][4]. Group 3: Law Firm Background - Wolf Haldenstein Adler Freeman & Herz LLP, founded in 1888, specializes in securities litigation and has a long history of advocating for investors who have suffered financial harm due to misrepresented statements [6]. - The firm encourages affected investors to contact them for assistance in the ongoing investigation [6].
Shareholders who lost money in shares Charming Medical Ltd. (NASDAQ: MCTA) Should Contact Wolf Haldenstein Immediately